Data gathered: November 25
AI Stock Analysis - Karyopharm Therapeutics (KPTI)
Analysis generated February 5, 2024. Powered by Chat GPT.
Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of novel cancer therapies. The company prides itself on its innovative periphery SINE compounds that alter the activity of nuclear export proteins. Its commitment to advancing the treatment landscape for patients with cancer is evident in its ongoing research and product development efforts.
Stock Alerts - Karyopharm Therapeutics (KPTI)
 |
Karyopharm Therapeutics | November 22 Price is up by 6.7% in the last 24h. |
|
Karyopharm Therapeutics | November 11 Price is up by 5.1% in the last 24h. |
|
Karyopharm Therapeutics | November 6 Price is up by 5.2% in the last 24h. |
|
Karyopharm Therapeutics | November 5 Price is down by -7.7% in the last 24h. |
Alternative Data for Karyopharm Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 10,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 31 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 879 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,901 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,603 | Sign up | Sign up | Sign up |
| Twitter Mentions | 29 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 63 | Sign up | Sign up | Sign up |
| Linkedin Employees | 387 | Sign up | Sign up | Sign up |
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
| Price | $0.84 |
| Target Price | Sign up |
| Volume | 451,760 |
| Market Cap | $106M |
| Year Range | $0.7 - $1.58 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Industry | Biotechnology |
In the news
 |
Karyopharm Therapeutics (NASDAQ:KPTI) Cut to Hold at StockNews.comNovember 22 - ETF Daily News |
 |
Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerNovember 20 - Yahoo |
Karyopharm Therapeutics : MPN 2024 SENTRY Ph 1 presentationNovember 14 - Finnhub |
|
|
What is HC Wainwright’s Estimate for KPTI FY2024 Earnings?November 9 - ETF Daily News |
|
Karyopharm Therapeutics Reports Q3 2024 Financial Results and Corporate ProgressNovember 8 - ETF Daily News |
 |
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?November 7 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 39M | 28M | 11M | -32M | -26M | -0.257 |
| Q2 '24 | 87M | 31M | 56M | 24M | -28M | 0.150 |
| Q1 '24 | 27M | 30M | -2.3M | -37M | -34M | -0.320 |
| Q4 '23 | 28M | 31M | -3.1M | -42M | -38M | -0.360 |
| Q3 '23 | 30M | 31M | -870,000 | -35M | -28M | -0.300 |
Insider Transactions View All
| Cheng Sohanya Roshan filed to sell 404,051 shares at $0.7. September 5 '24 |
| Mason Michael filed to sell 391,054 shares at $0.7. September 5 '24 |
| Paulson Richard A. filed to sell 1,139,214 shares at $0.7. September 5 '24 |
| Mano Michael filed to sell 273,881 shares at $0.7. September 5 '24 |
| Paulson Richard A. filed to sell 1,142,881 shares at $0.9. August 8 '24 |
Similar companies
Read more about Karyopharm Therapeutics (KPTI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Karyopharm Therapeutics?
The Market Cap of Karyopharm Therapeutics is $106M.
What is the current stock price of Karyopharm Therapeutics?
Currently, the price of one share of Karyopharm Therapeutics stock is $0.84.
How can I analyze the KPTI stock price chart for investment decisions?
The KPTI stock price chart above provides a comprehensive visual representation of Karyopharm Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Karyopharm Therapeutics shares. Our platform offers an up-to-date KPTI stock price chart, along with technical data analysis and alternative data insights.
Does KPTI offer dividends to its shareholders?
As of our latest update, Karyopharm Therapeutics (KPTI) does not offer dividends to its shareholders. Investors interested in Karyopharm Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Karyopharm Therapeutics?
Some of the similar stocks of Karyopharm Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.